Background/Aims: To investigate the downregulation of microRNA (miR)-10b in clear cell renal cell carcinoma (ccRCC) and its mechanistic involvement in tumourigenesis. Methods: The relative expression of miR-10b in ccRCC samples were determined by real-time PCR. Exogenous expression and knockdown of endogenous miR-10b were performed by transfection with indicated plasmids into 786-0 cells. Cell proliferation was evaluated using Cell Counting Kit-8 assay. Cell apoptosis was analyzed by Annexin V/propidium iodide staining. MAPK pathway activation was detected by western blotting with indicated antibodies. Results: We confirmed the downregulation of miR-10b in ccRCC tumour. The forced expression of miR-10b inhibited cell proliferation in 786-0 cells. Moreover, miR-10b stimulated apoptosis in 786-0 cells, which was abrogated by specific miR-10b inhibitor. We further elucidated that the apoptosis induction was mediated by the JNK pathway activation. We consolidated this observation by combinational treatment with JNK specific inhibitor, which was shown to completely impede miR-10b elicited apoptosis. Conclusion: We suggested a tumour suppressor function of miR-10b in tumourigenesis of ccRCC via proliferation suppression and apoptosis induction, and the latter was mediated by the JNK pathway activation.

Keywords:
MicroRNA-10b, Proliferation, Apoptosis, JNK pathway, Clear cell renal cell carcinoma
1.
Capitanio U, Montorsi F: Renal cancer. Lancet 2016; 387: 894–906.
2.
Choueiri TK, Pomerantz MM, Signoretti S: Renal-cell carcinoma: a step closer to a new classification. Lancet Oncol 2013; 14: 105–107.
3.
Siegel R, Ma J, Zou Z, Jemal A: Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
4.
Lopez-Beltran A, Cheng L, Vidal A, Scarpelli M, Kirkali Z, Blanca A, Montironi R: Pathology of renal cell carcinoma: an update. Anal Quant Cytopathol Histpathol 2013; 35: 61–76.
5.
Ljungberg B, Campbell SC, Choi HY, Jacqmin D, Lee JE, Weikert S, Kiemeney LA: The epidemiology of renal cell carcinoma. Eur Urol 2011; 60: 615–621.
6.
Shen C, Kaelin WG Jr: The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol 2013; 23: 18–25.
7.
Gossage L, Eisen T, Maher ER: VHL, the story of a tumour suppressor gene. Nat Rev Cancer 2015; 15: 55–64.
8.
Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaipparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA; Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ: The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014; 26: 319–330.
9.
Haddad AQ, Margulis V: Tumour and patient factors in renal cell carcinoma-towards personalized therapy. Nat Rev Urol 2015; 12: 253–262.
10.
Pal SK, Haas NB: Adjuvant therapy for renal cell carcinoma: past, present, and future. Oncologist 2014; 19: 851–859.
11.
Funakoshi T, Lee CH, Hsieh JJ: A systematic review of predictive and prognostic biomarkers for VEGF-targeted therapy in renal cell carcinoma. Cancer Treat Rev 2014; 40: 533–547.
12.
Thomas JS, Kabbinavar F: Metastatic clear cell renal cell carcinoma: a review of current therapies and novel immunotherapies. Crit Rev Oncol Hematol 2015; 96: 527–533.
13.
Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281–297.
14.
Kiselev FL: [MicroRNA and cancer]. Mol Biol (Mosk) 2014; 48: 232–242.
15.
Hayes J, Peruzzi PP, Lawler S: MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 2014; 20: 460–469.
16.
Khella HW, Daniel N, Youssef L, Scorilas A, Nofech-Mozes R, Mirham L, Krylov SN, Liandeau E, Krizova A, Finelli A, Cheng Y, Yousef GM: miR-10b is a prognostic marker in clear cell renal cell carcinoma. J Clin Pathol 2017; 70: 854–859.
17.
Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, Wu JJ, Ruel NH, Wilczynski SP, Gao H, Covarrubias M, Figlin RA, Weiss LM, Wu H: Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS One 2012; 7:e35661.
18.
Ding XM: MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin J Cancer 2014; 33: 140–147.
19.
Sun X, Lou L, Zhong K, Wan L: MicroRNA-451 regulates chemoresistance in renal cell carcinoma by targeting ATF-2 gene. Exp Biol Med (Maywood) 2017: 1535370217701625.
20.
Gu DH, Mao JH, Pan XD, Zhu H, Chen X, Zheng B, Shan Y: MicroRNA-302c-3p inhibits renal cell carcinoma cell proliferation by targeting Grb2-associated binding 2 (Gab2). Oncotarget 2017; 8: 26334–26343.
21.
Huang H, Xiong G, Shen P, Cao Z, Zheng L, Zhang T, Zhao Y: MicroRNA-1285 inhibits malignant biological behaviors of human pancreatic cancer cells by negative regulation of YAP1. Neoplasma 2017; 64: 358–366.
22.
Li Y, Li Y, Liu J, Fan Y, Li X, Dong M, Liu H, Chen J: Expression levels of microRNA-145 and microRNA-10b are associated with metastasis in non-small cell lung cancer. Cancer Biol Ther 2016; 17: 272–279.
23.
Sun L, Yan W, Wang Y, Sun G, Luo H, Zhang J, Wang X, You Y, Yang Z, Liu N: MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Res 2011; 1389: 9–18.
24.
Wang YY, Li L, Ye ZY, Zhao ZS, Yan ZL: MicroRNA-10b promotes migration and invasion through Hoxd10 in human gastric cancer. World J Surg Oncol 2015; 13: 259.
25.
Ahmad A, Sethi S, Chen W, Ali-Fehmi R, Mittal S, Sarkar FH: Up-regulation of microRNA-10b is associated with the development of breast cancer brain metastasis. Am J Transl Res 2014; 6: 384–390.
26.
Li Y, Chen D, Li Y, Jin L, Liu J, Su Z, Qi Z, Shi M, Jiang Z, Ni L, Yang S, Gui Y, Mao X, Chen Y, Lai Y: Oncogenic cAMP responsive element binding protein 1 is overexpressed upon loss of tumor suppressive miR-10b-5p and miR-363-3p in renal cancer. Oncol Rep 2016; 35: 1967–1978.
27.
Knirsh R, Ben-Dror I, Modai S, Shomron N, Vardimon L: MicroRNA 10b promotes abnormal expression of the proto-oncogene c-Jun in metastatic breast cancer cells. Oncotarget 2016; 7: 59932–59944.
28.
Wang J, Wang B, Chen LQ, Yang J, Gong ZQ, Zhao XL, Zhang CQ, Du KL: MiR-10b promotes invasion by targeting KLF4 in osteosarcoma cells. Biomed Pharmacother 2016; 84: 947–953.
29.
Zhang P, Hong H, Sun X, Jiang H, Ma S, Zhao S, Zhang M, Wang Z, Jiang C, Liu H: MicroRNA-10b regulates epithelial-mesenchymal transition by modulating KLF4/Notch1/E-cadherin in cisplatin-resistant nasopharyngeal carcinoma cells. Am J Cancer Res 2016; 6: 141–156.
30.
Ma Z, Chen Y, Min L, Li L, Huang H, Li J, Yan Q, Song P, Dai L, Yao X: Augmented miR-10b expression associated with depressed expression of its target gene KLF4 involved in gastric carcinoma. Int J Clin Exp Pathol 2015; 8: 5071–5079.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.